Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.59 |
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14443028 | 0.83 | KMT2A (0.56) | ALDH1A1CXCR1CXCR2 | |
| SCHEMBL14318501 | 0.83 | CA2 (0.56) | CA12CA1CA2CA9CA7 | |
| SCHEMBL16479548 | 0.79 | CA2 (0.66) | CA12CA1CA2CA9CA7 | |
| SCHEMBL1870820 | 0.79 | CA1 (0.66) | CA12CA1CA2CA9CA7 | |
| SCHEMBL27565494 | 0.76 | CA2 (0.68) | CA12CA1CA2CA9CA7 | |
| SCHEMBL14380626 | 0.75 | MEN1 (0.70) | CA12CA1CA2CA9CA7 | |
| SCHEMBL688459 | 0.75 | CA1 (0.54) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL14380636 | 0.75 | CA2 (0.66) | CA12CA1CA2CA9CA7 | |
| SCHEMBL3092073 | 0.75 | CA2 (0.61) | CA12CA1CA2CA9CA7 | |
| SCHEMBL6552067 | 0.74 | CA1 (0.70) | CA12CA1CA2CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133128-B2 | Pyrazole derivatives as cannabinoid receptor 1 antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140107157-A1 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2014-04-17 | — | — | US | disclosed |
| WO-2012174362-A1 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107157-A1 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | CNR1, CNR2, GPR119 | CA12 4795/4885CA1 4738/4885CA2 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.